Milestone Pharmaceuticals Inc
Research Milestone Pharmaceuticals Inc (MIST) on Bullrun: market cap USD 100.35M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMIST
- ExchangeNASDAQ
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 100.35M
- Financial periodQ2 2026
- RevenueUSD 559.00K
- Net income-USD 28.61M
- Free cash flow-USD 22.74M
- Gross margin94.3%
Valuation Snapshot
latest market cap is USD 100.35M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.55M | -USD 63.06K | -USD 49.34M | n/a | -0.75 | USD 73.05M | USD 57.19M | USD 41.77M |
| FY2024 | USD 0 | -USD 41.52K | -USD 28.88M | n/a | -0.67 | USD 25.31M | USD 53.35M | USD 13.15M |
| FY2023 | USD 1.00M | -USD 59.69K | -USD 46.54M | n/a | -1.39 | USD 13.76M | USD 49.77M | USD 16.77M |
| FY2022 | USD 5.00M | -USD 58.39M | -USD 52.74M | n/a | -1.38 | USD 7.64M | USD 2.49M | USD 66.35M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 100.35M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 214.60M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 125.92M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 55.92M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 135.77M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 195.83M | n/a | n/a | n/a |
About Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR).
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Milestone Pharmaceuticals Inc's market cap?
Milestone Pharmaceuticals Inc's market capitalization is USD 100.35M.
What does Milestone Pharmaceuticals Inc do?
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR).